Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avacincaptad pegol + ranibizumab
- Development stage
- Phase 2
- Lead developer
- Astellas Pharma
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
Avacincaptad pegol + ranibizumab is a combination therapy investigated for the treatment of neovascular age-related macular degeneration (nAMD). Avacincaptad pegol is a pegylated RNA aptamer that specifically binds to complement component C5, inhibiting its cleavage into C5a and C5b, thereby blocking the terminal steps of the complement cascade. This action reduces membrane attack complex (MAC) formation and subsequent retinal pigment epithelium (RPE) disruption, aiming to slow photoreceptor and RPE atrophy. Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the retina. The combination targets both complement-mediated inflammation/atrophy and VEGF-driven neovascularization in nAMD[1][2][4].
- Brand names
- Zimura
- Other names
- ARC1905 + Lucentisavacincaptad pegol + ranibizumab combination
02
Targets
Beyond the preview
Go deeper on avacincaptad pegol + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avacincaptad pegol + ranibizumab.